| Publikationen |
 |
 |
|
2012 Off-label therapy of rheumatoid arthritis and spondyloarthritis. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J. Ann Rheum Dis. 2012 Apr;71(4):572-4.
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, Fitzgerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. Ann Rheum Dis. 2012 Jan;71(1):4-12.
2011 Baseline radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Arthritis Rheum. 2011 Nov 29. doi: 10.1002/art.33465. [Epub ahead of print]
Evaluation of the spinal pain score in AS – a psychometric analysis. Song IH, Haibel H, Stelling ES, Sieper J, Rudwaleit M. Rheumatology (Oxford). 2011 Dec 11. [Epub ahead of print]
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Ann Rheum Dis. 2011 Nov 29. [Epub ahead of print]
Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. Poddubnyy D, Vahldiek J, Spiller I, Buss B, Listing J, Rudwaleit M, Sieper J. J Rheumatol. 2011 Nov;38(11):2452-60.
Relation of HLA-B27, tumor necrosis factor-a promoter gene polymorphisms, and T cell cytokine production in ankylosing Spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort. Poddubnyy DA, Märker-Hermann E, Kaluza-Schilling W, Zeidler H, Braun J, Listing J, Sieper J, Rudwaleit M. J Rheumatol. 2011 Nov;38(11):2436-41.
Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. Appel H, Wu P, Scheer R, Kedor C, Sawitzki B, Thiel A, Radbruch A, Sieper J, Syrbe U. J Rheumatol. 2011 Nov;38(11):2445-51.
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. Clin Exp Rheumatol. 2011 Jul-Aug;29(4):672-80.
Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn's Disease and Ankylosing Spondylitis. Ergin A, Syrbe U, Scheer R, Thiel A, Adam T, Büssow K, Duchmann R, Zeitz M, Sieper J. J Clin Immunol. 2011 Dec;31(6):998-1009.
IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ. PLoS One. 2011;6(8):e24048.
Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. Grazio S, Kusic Z, Cvijetic S, Grubišic F, Balenovic A, Nemcic T, Matijevic-Mikelic V, Punda M, Sieper J. Rheumatol Int. 2011 Aug 20. [Epub ahead of print]
Development of morbidity and mortality in patients with spondyloarthritis. Kiltz U, Sieper J, Braun J. Z Rheumatol. 2011 Aug;70(6):473-9.
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J. Arthritis Res Ther. 2011 Jun 20;13(3):R95.
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J. Rheumatology (Oxford). 2011 Sep;50(9):1690-9.
New treatment targets in ankylosing spondylitis and other spondyloarthritides. Song IH, Poddubnyy D. Curr Opin Rheumatol. 2011;23:346-351.
Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Ann Rheum Dis. 2011;70:1369-1374.
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Freundlich B, Rudwaleit M, Sieper J. Ann Rheum Dis. 2011;70:1257-1263.
Spondyloarthritides. Braun J, Rudwaleit M, Sieper J. Internist (Berl). 2011;52:657-670.
van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J; for the Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2011;70:905-908.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman R, Jongkees M, Khan M, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych W, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. Ann Rheum Dis. 2011;70:896-904.
Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiß A, Braun J, Sieper J. Ann Rheum Dis. 2011;70:1108-1110. Predicting the outcome of ankylosing spondylitis therapy. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Ann Rheum Dis. 2011;70:973-81. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Song IH, Hermann K, Haibel H, Althoff C, Listing J, Burmester G, Krause A, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J. Ann Rheum Dis. 2011;70:590-6.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Ann Rheum Dis. 2011;70 Suppl 1:i2-36. Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond. Sieper J. Nat Rev Rheumatol. 2011;7:78-80. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. Ann Rheum Dis. 2011;70:249-51.
2010 Current controversies in spondyloarthritis: SPARTAN. Weisman M, Learch TJ, Baraliakos X, Chandran V, Gladman DD, Raychaudhuri SP, Xu H, Collantes-Estévez E, Vázquez-Mellado J, Mease PJ, Sieper J, Deodhar AA, Colbert RA, Clegg DO; SPARTAN Group. J Rheumatol. 2010;37:2617-23. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J. Ann Rheum Dis. 2011;70:25-31. Use of methotrexate in patients with ankylosing spondylitis. Haibel H, Sieper J. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S128-31. Investigation of involved tissue in axial spondyloarthritis--what have we learnt from immunohistochemical studies?
Essential methodological improvements in the oxygen isotope ratio analysis of N-containing organic compounds. Sieper HP, Kupka HJ, Lange L, Rossmann A, Tanz N, Schmidt HL. Rapid Commun Mass Spectrom. 2010;24:2849-58.
Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Haibel H, Sieper J. Curr Opin Rheumatol. 2010;22:388-92.
Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Poddubnyy D, Rudwaleit M, Listing J, Braun J, Sieper J. Ann Rheum Dis. 2010;69:1338-41.
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Martin Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, Koenig AS, Freundlich B. Clin Exp Rheumatol. 2010;28:238-45.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dorner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Ann Rheum Dis. 2010;69 Suppl 1:i2-29.
Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Rheumatology (Oxford). 2010;49:1578-89.
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Arthritis Res Ther. 2010;12:R43.
Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. Appel H, Maier R, Loddenkemper C, Kayser R, Meier O, Hempfing A, Sieper J. J Rheumatol. 2010;37:823-8.
Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis. Song IH, Brandt H, Rudwaleit M, Sieper J. J Rheumatol. 2010;37:1200-2.
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Arthritis Rheum. 2010;62:1290-7.
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B. Ann Rheum Dis. 2010;69:226-9.
2009 Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G. Arthritis Rheum. 2009;60:3257-62.
Adalimumab for the treatment of psoriatic arthritis. Poddubnyy DA, Rudwaleit M. Expert Rev Clin Immunol. 2009;5:671-81.
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, Thompson C, Sieper J. Arthritis Res Ther. 2009;11:R124.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Lancet. 2009;374:210-21.
HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: potential contribution to local immunopathologic processes in ankylosing spondylitis. Kuhne M, Erben U, Schulze-Tanzil G, Kohler D, Wu P, Richter FJ, John T, Radbruch A, Sieper J, Appel H. Arthritis Rheum. 2009;60:1635-46.
Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Arthritis Rheum. 2009;61:764-71.
Role of whole-body magnetic resonance imaging in diagnosing early spondyloarthritis. Mager AK, Althoff CE, Sieper J, Hamm B, Hermann KG. Eur J Radiol. 2009;71:182-8.
Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rudwaleit M, Olivieri I, Boki KA, Griep EN, Jarvinen P, Wong RL, Kron M, Kary S, Kupper H. Rheumatology (Oxford). 2009;48:551-7.
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Ann Rheum Dis. 2009;68:696-701.
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J. Ann Rheum Dis. 2009;68:1520-7.
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewe R, Maksymowych W, van der Heijde D. Ann Rheum Dis. 2009;68 Suppl 2:ii1-44.
Can structural damage be prevented in ankylosing spondylitis? Sieper J. Curr Opin Rheumatol. 2009;21:335-9.
Etanercept in the longterm treatment of patients with ankylosing spondylitis. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J. J Rheumatol. 2009;36:1256-64.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. Ann Rheum Dis. 2009;68:770-6.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. Ann Rheum Dis. 2009;68:777-83.
Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S. J Rheumatol. 2009;36:801-8.
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Arthritis Rheum. 2009;60:717-27.
Developments in the scientific and clinical understanding of the spondyloarthritides. Sieper J. Arthritis Res Ther. 2009;11:208.
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Sieper J, van der Heijde D, Landewe R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Rudwaleit M. Ann Rheum Dis. 2009;68:784-8.
Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. Sattler A, Wagner U, Rossol M, Sieper J, Wu P, Krause A, Schmidt WA, Radmer S, Kohler S, Romagnani C, Thiel A. Blood. 2009;113:1948-56.
Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Song IH, Rudwaleit M, Listing J, Sieper J. Ann Rheum Dis. 2009;68:1701-7.
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC, Jr. Ann Rheum Dis. 2009;68:922-9.
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Ann Rheum Dis. 2009;68:18-24.
2008
Identification of the predominant antigenic epitopes in intestinal flora in IBD. Ergin A, Adam T, Bussow K, Thiel A, Sieper J, Duchmann R. Mucosal Immunol. 2008;1 Suppl 1:S19-23.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dorner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Ann Rheum Dis. 2008;67 Suppl 3:iii2-25.
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R. Ann Rheum Dis. 2009;68:1811-8.
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Inman RD, Davis JC, Jr., Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Arthritis Rheum. 2008;58:3402-12.
Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Arthritis Res Ther. 2008;10:R125.
Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Appel H, Rudwaleit M, Sieper J. Nat Clin Pract Rheumatol. 2008;4:578-9.
Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. Appel H, Sieper J. Curr Rheumatol Rep. 2008;10:356-63.
What is the most important outcome parameter in ankylosing spondylitis? Braun J, Sieper J. Rheumatology (Oxford). 2008;47:1738-40.
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Arthritis Res Ther. 2008;10:R104.
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D. Arthritis Rheum. 2008;59:1270-8.
Autoregulation of Th1-mediated inflammation by twist1. Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, Eulenburg K, Kreher S, Koeck J, Baumgrass R, Bonhagen K, Kamradt T, Enghard P, Humrich JY, Rutz S, Schulze-Topphoff U, Aktas O, Bartfeld S, Radbruch H, Hegazy AN, Lohning M, Baumgart DC, Duchmann R, Rudwaleit M, Haupl T, Gitelman I, Krenn V, Gruen J, Sieper J, Zeitz M, Wiedenmann B, Zipp F, Hamann A, Janitz M, Scheffold A, Burmester GR, Chang HD, Radbruch A. J Exp Med. 2008;205:1889-901.
The safety of celecoxib in ankylosing spondylitis treatment. Poddubnyy DA, Song IH, Sieper J. Expert Opin Drug Saf. 2008;7:401-9.
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J. Arthritis Rheum. 2008;58:1981-91.
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Haibel H, Song IH, Rudwaleit M, Listing J, Hildemann S, Sieper J. Clin Exp Rheumatol. 2008;26:247-52.
Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment? Sieper J. Nat Clin Pract Rheumatol. 2008;4:398-9.
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T. Arthritis Res Ther. 2008;10:R67.
Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC, Jr. J Rheumatol. 2008;35:1346-53.
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Arthritis Rheum. 2008;58:929-38.
Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. Zochling J, Sieper J, van der Heijde D, Braun J. J Rheumatol. 2008;35:1079-82.
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Sieper J, Appel H, Braun J, Rudwaleit M. Arthritis Rheum. 2008;58:649-56.
From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. Steinbrich-Zollner M, Grun JR, Kaiser T, Biesen R, Raba K, Wu P, Thiel A, Rudwaleit M, Sieper J, Burmester GR, Radbruch A, Grutzkau A. Cytometry A. 2008;73:333-40.
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Sidiropoulos PI, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, Herold M, Kvien TK, Mielants H, Mendoza JM, Olivieri I, Ostergaard M, Schachna L, Sieper J, Boumpas DT, Dougados M. Rheumatology (Oxford). 2008;47:355-61.
The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Song IH, Carrasco-Fernandez J, Rudwaleit M, Sieper J. Ann Rheum Dis. 2008;67:1535-40.
New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M. J Rheumatol. 2008;35:532-6.
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, Pham T, Braun J, Sieper J, Olivieri I, van der Heijde D, Collantes E, Stone M, Kvien TK. Ann Rheum Dis. 2008;67:782-8.
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. Ann Rheum Dis. 2008;67:1276-81.
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sorensen H, Zeidler H, Sieper J. Ann Rheum Dis. 2008;67:340-5.
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M. Ann Rheum Dis. 2008;67:323-9.
2007
Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab. Appel H, Hermann KG, Althoff CE, Rudwaleit M, Sieper J. J Rheumatol. 2007;34:2497-8.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Ann Rheum Dis. 2007;66 Suppl 3:iii2-22.
In vitro observations of T cell responsiveness to recall antigens during tumor necrosis factor-alpha-blocking therapy in patients with ankylosing spondylitis. Appel H, Scheer R, Haibel H, Wu P, Spiller I, Brandt H, Song IH, Rudwaleit M, Thiel A, Sieper J. J Rheumatol. 2007;34:2264-70.
Diagnosing early ankylosing spondylitis. Song IH, Sieper J, Rudwaleit M. Curr Rheumatol Rep. 2007;9:367-74.
IL-10 is excluded from the functional cytokine memory of human CD4+ memory T lymphocytes. Dong J, Ivascu C, Chang HD, Wu P, Angeli R, Maggi L, Eckhardt F, Tykocinski L, Haefliger C, Mowes B, Sieper J, Radbruch A, Annunziato F, Thiel A. J Immunol. 2007;179:2389-96.
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Rheumatology (Oxford). 2007;46:1450-3.
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Kobelt G, Sobocki P, Sieper J, Braun J. Int J Technol Assess Health Care. 2007;23:368-75.
Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis. Althoff CE, Appel H, Rudwaleit M, Sieper J, Eshed I, Hamm B, Hermann KG. Ann Rheum Dis. 2007;66:983-5.
Homologous high-throughput expression and purification of highly conserved E coli proteins. Ergin A, Bussow K, Sieper J, Thiel A, Duchmann R, Adam T. Microb Cell Fact. 2007;6:18.
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Arthritis Rheum. 2007;57:639-47.
A case of axial undifferentiated spondyloarthritis diagnosis and management. Rudwaleit M, Sieper J. Nat Clin Pract Rheumatol. 2007;3:298-303.
Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Brandt HC, Spiller I, Song IH, Vahldiek JL, Rudwaleit M, Sieper J. Ann Rheum Dis. 2007;66:1479-84.
Ankylosing spondylitis. Braun J, Sieper J. Lancet. 2007;369:1379-90.
Adalimumab for the treatment of ankylosing spondylitis. Sieper J, Rudwaleit M, Braun J. Expert Opin Pharmacother. 2007;8:831-8.
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Ann Rheum Dis. 2007;66:910-5.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sorensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. J Rheumatol. 2007;34:510-5.
Identification of immunodominant CD4+ T cell epitopes in patients with Yersinia-induced reactive arthritis by cytometric cytokine secretion assay. Thiel A, Wu P, Lanowska M, Dong J, Radbruch A, Sieper J. Arthritis Rheum. 2006;54:3583-90.
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J. Ann Rheum Dis. 2007;66:419-21.
2006
Early diagnosis of spondyloarthritis. Braun J, Sieper J. Nat Clin Pract Rheumatol. 2006;2:536-45.
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S. Ann Rheum Dis. 2006;65:1572-7.
Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. Tryc AB, Spies CM, Schneider U, Kunkel D, Berki T, Sieper J, Burmester GR, Radbruch A, Scheffold A, Buttgereit F. J Rheumatol. 2006;33:2249-53.
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Kohler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C. Arthritis Rheum. 2006;54:2845-51.
Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, Stein H, Metz-Stavenhagen P, Rudwaleit M, Sieper J. Arthritis Res Ther. 2006;8:R143.
Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Rudwaleit M, Feldtkeller E, Sieper J. Ann Rheum Dis. 2006;65:1251-2.
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, Jr. Arthritis Rheum. 2006;54:2136-46.
Concepts and epidemiology of spondyloarthritis. Sieper J, Rudwaleit M, Khan MA, Braun J. Best Pract Res Clin Rheumatol. 2006;20:401-17.
Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Appel H, Kuhne M, Spiekermann S, Kohler D, Zacher J, Stein H, Sieper J, Loddenkemper C. Arthritis Rheum. 2006;54:1805-13.
Can unresolved infection precipitate autoimmune disease? Marks DJ, Mitchison NA, Segal AW, Sieper J. Curr Top Microbiol Immunol. 2006;305:105-25.
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Ann Rheum Dis. 2006;65:1147-53.
Positive and negative predictive values from published studies can be misleading for decision-making in clinical practice. Rudwaleit M, Sieper J. Rheumatology (Oxford). 2006;45:779-80; author reply 80-1.
Definition of disease duration in ankylosing spondylitis: reassessing the concept. Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. Ann Rheum Dis. 2006;65:1518-20.
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Pham T, Landewe R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D. Ann Rheum Dis. 2006;65:1620-5.
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J. Arthritis Rheum. 2006;54:678-81.
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Arthritis Rheum. 2006;54:569-78.
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, Gromnica-Ihle E, von Hinueber U, Wassenberg S, Genth E, Schneider M. J Rheumatol. 2006;33:86-90.
Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Francois RJ, Neure L, Sieper J, Braun J. Ann Rheum Dis. 2006;65:713-20.
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Jr., Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J. Ann Rheum Dis. 2006;65:442-52.
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. Ann Rheum Dis. 2006;65:316-20.
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewe R, Braun J, Brandt J, Sieper J, van der Linden S. Ann Rheum Dis. 2006;65:201-8.
2005 Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Rheumatology (Oxford). 2005;44:1525-30.
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Sieper J, Rudwaleit M. Ann Rheum Dis. 2005;64:659-63.
CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. Kohler S, Thiel A, Rudwaleit M, Sieper J, Braun J. Clin Exp Rheumatol. 2005;23:840-6.
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Arthritis Rheum. 2005;53:856-63.
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Sieper J, Rudwaleit M. Ann Rheum Dis. 2005;64 Suppl 4:iv61-4.
Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts. Bollow M, Hermann KG, Biedermann T, Sieper J, Schontube M, Braun J. Ann Rheum Dis. 2005;64:1644-6.
Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Braun J, Baraliakos X, Brandt J, Sieper J. Scand J Rheumatol. 2005;34:178-90.
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Rheumatology (Oxford). 2005;44:1525-30.
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Braun J, Baraliakos X, Listing J, Sieper J. Arthritis Rheum. 2005;52:2447-51.
Infliximab for the treatment of ankylosing spondylitis. Rudwaleit M, Sieper J. Expert Opin Biol Ther. 2005;5:1095-109.
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. J Rheumatol. 2005;32:1290-8.
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Arthritis Res Ther. 2005;7:R439-44.
Diverse effects of infliximab and etanercept on T lymphocytes. Sieper J, Van Den Brande J. Semin Arthritis Rheum. 2005;34:23-7.
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Rudwaleit M, Khan MA, Sieper J. Arthritis Rheum. 2005;52:1000-8.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Ann Rheum Dis. 2005;64:1305-10.
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Ann Rheum Dis. 2005;64:1462-6.
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J. Rheumatology (Oxford). 2005;44:670-6.
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J. Arthritis Rheum. 2005;52:892-901.
ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? van der Heijde D, Braun J, Landewe R, Davis J, Sieper J, van der Linden S, Dougados M. Ann Rheum Dis. 2005;64 Suppl 2:ii108-9.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Arthritis Rheum. 2005;52:582-91.
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Baraliakos X, Hermann KG, Landewe R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Ann Rheum Dis. 2005;64:1141-4.
Six months open label trial of leflunomide in active ankylosing spondylitis. Haibel H, Rudwaleit M, Braun J, Sieper J. Ann Rheum Dis. 2005;64:124-6.
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Rheumatology (Oxford). 2005;44:342-8.
Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Zou J, Appel H, Rudwaleit M, Thiel A, Sieper J. Ann Rheum Dis. 2005;64:722-9.
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Sieper J, Rudwaleit M. Ann Rheum Dis. 2005;64:659-63.
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Ann Rheum Dis. 2005;64:730-4.
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J. Ann Rheum Dis. 2005;64:229-34.
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Haibel H, Rudwaleit M, Listing J, Sieper J. Ann Rheum Dis. 2005;64:296-8.
2004
The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes. Appel H, Kuon W, Kuhne M, Hulsmeyer M, Kollnberger S, Kuhlmann S, Weiss E, Zeitz M, Wucherpfennig K, Bowness P, Sieper J. J Immunol. 2004;173:6564-73.
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Ann Rheum Dis. 2004;63:1670-2.
Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Appel H, Kuon W, Kuhne M, Wu P, Kuhlmann S, Kollnberger S, Thiel A, Bowness P, Sieper J. Arthritis Res Ther. 2004;6:R521-34.
Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. Kuon W, Kuhne M, Busch DH, Atagunduz P, Seipel M, Wu P, Morawietz L, Fernahl G, Appel H, Weiss EH, Krenn V, Sieper J. J Immunol. 2004;173:4859-66.
Workshop report: clinical diagnosis and imaging of sacroiliitis, Innsbruck, Austria, October 9, 2003. Klauser A, Bollow M, Calin A, Frauscher F, Kainberger F, Moncayo R, Salvarani C, Sieper J, zur Nedden D, Schirmer M. J Rheumatol. 2004;31:2041-7.
An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Appel H, Neure L, Kuhne M, Braun J, Rudwaleit M, Sieper J. Clin Rheumatol. 2004;23:435-40.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S. Ann Rheum Dis. 2004;63:1594-600.
Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. Golder W, Karberg K, Sieper J. Clin Rheumatol. 2004;23:481-4.
Biological therapies in the spondyloarthritides--the current state. Braun J, Sieper J. Rheumatology (Oxford). 2004;43:1072-84.
How to diagnose axial spondyloarthritis early. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. Ann Rheum Dis. 2004;63:535-43.
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, Rudwaleit M, Zuehlsdorf S, Bollow M, Sieper J, van der Heijde D. Ann Rheum Dis. 2004;63:1046-55.
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Ann Rheum Dis. 2004;63:1438-44.
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Ann Rheum Dis. 2004;63:665-70.
Disease mechanisms in reactive arthritis. Sieper J. Curr Rheumatol Rep. 2004;6:110-6.
Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. J Rheumatol. 2004;31:531-8.
2003
Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. Braun J, Sieper J, van der Heijde D. Ann Rheum Dis. 2003;62:1023-4.
Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis. Kuon W, Sieper J. Rheum Dis Clin North Am. 2003;29:595-611.
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D. Ann Rheum Dis. 2003;62:817-24.
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J. Arthritis Rheum. 2003;48:2224-33.
Treatment of active ankylosing spondylitis with pamidronate. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Rheumatology (Oxford). 2003;42:1018-20.
Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Curr Opin Rheumatol. 2003;15:394-407.
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Arthritis Rheum. 2003;48:1667-75.
Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical Escherichia coli Shigella isolates. Adam T, Siewerdt R, Offermann I, Lang J, Tschape H, Sieper J, Graf B. Microbes Infect. 2003;5:579-92.
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Ann Rheum Dis. 2003;62:561-4.
Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. Braun J, Sieper J. BioDrugs. 2003;17:187-99.
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J. Arthritis Rheum. 2003;48:1374-84.
Congenital absence of the portal vein with splenomegaly and hypersplenism in a young woman. Appel H, Loddenkemper C, Schirmacher P, Dienes HP, Sieper J, Rudwaleit M, Golder W, Zeitz M. Digestion. 2003;67:105-10.
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, Poole R, Braun J, Sieper J. Rheumatology (Oxford). 2003;42:846-55.
Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Braun J, Sieper J. Expert Opin Biol Ther. 2003;3:141-68.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D. Arthritis Rheum. 2003;48:1126-36.
Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. Stebbing J, Bourboulia D, Johnson M, Henderson S, Williams I, Wilder N, Tyrer M, Youle M, Imami N, Kobu T, Kuon W, Sieper J, Gotch F, Boshoff C. J Virol. 2003;77:4306-14.
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Arthritis Rheum. 2003;48:780-90.
2002 Ankylosing spondylitis: an overview. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ann Rheum Dis. 2002;61 Suppl 3:iii8-18.
Anti-TNF agents for the treatment of spondyloarthropathies. Sieper J, Braun J. Expert Opin Emerg Drugs. 2002;7:235-46.
Anti-TNF therapy and the spondyloarthritides: who should be treated? Braun J, Sieper J. Clin Exp Rheumatol. 2002;20:S187.
Imaging and scoring in ankylosing spondylitis. Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Clin Exp Rheumatol. 2002;20:S178-84.
Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Bollow M, Enzweiler C, Taupitz M, Golder W, Hamm B, Sieper J, Braun J. Clin Exp Rheumatol. 2002;20:S167-74.
Infliximab in the treatment of active and severe ankylosing spondylitis. Brandt J, Sieper J, Braun J. Clin Exp Rheumatol. 2002;20:S106-10.
Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Zou JX, Braun J, Sieper J. Clin Exp Rheumatol. 2002;20:S34-7.
Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. Braun J, Sieper J. Ann Rheum Dis. 2002;61 Suppl 3:iii61-7.
Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Ann Rheum Dis. 2002;61 Suppl 3:iii51-60.
Staging of patients with ankylosing spondylitis: a preliminary proposal. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, van der Linden S. Ann Rheum Dis. 2002;61 Suppl 3:iii9-23.
Ankylosing spondylitis: an overview. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ann Rheum Dis. 2002;61 Suppl 3:iii8-18.
New treatment strategies in ankylosing spondylitis: Proceedings of the Ankylosing Spondylitis Workshop, Berlin, Germany, 18-19 January 2002. Sieper J, Braun J. Ann Rheum Dis. 2002;61 Suppl 3:iii1-2.
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Rudwaleit M, Andermann B, Alten R, Sorensen H, Listing J, Zink A, Sieper J, Braun J. Ann Rheum Dis. 2002;61:968-74.
Massive splenomegaly and hypersplenism in a young woman with primary Sjogren's syndrome. Appel H, Loddenkemper C, Rohweder J, Rudwaleit M, Zeitz M, Sieper J. J Rheumatol. 2002;29:2012-3.
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Braun J, Sieper J. Arthritis Res. 2002;4:307-21.
Association of HLA-DRB1*02 with osteoarthritis in a cohort of 106 patients. Moos V, Menard J, Sieper J, Sparmann M, Muller B. Rheumatology (Oxford). 2002;41:666-9.
The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. Burgos-Vargas R, Rudwaleit M, Sieper J. J Rheumatol. 2002;29:869-74.
Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteria. Appel H, Rudwaleit M, Wu P, Grolms M, Sieper J, Mertz A. Ann Rheum Dis. 2002;61:566-7.
T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. Zou J, Rudwaleit M, Thiel A, Lauster R, Braun J, Sieper J. Ann Rheum Dis. 2002;61:473-4.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Lancet. 2002;359:1187-93.
Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjogren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. Brandt J, Maier T, Rudwaleit M, Kuhl U, Hiepe F, Sieper J, Braun J. Clin Exp Rheumatol. 2002;20:80-4.
Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Sieper J, Rudwaleit M, Braun J, van der Heijde D. Arthritis Rheum. 2002;46:319-27.
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. J Rheumatol. 2002;29:118-22.
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. Machein U, Buss B, Spiller I, Braun J, Rudwaleit M, Faerber L, Sieper J. Rheumatology (Oxford). 2002;41:110-1.
2001
New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. Sieper J, Braun J. Ann Rheum Dis. 2001;60 Suppl 3:iii58-61.
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Arthritis Rheum. 2001;44:2936-7.
Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants. Moo V, Sieper J, Herzog V, Muller BM. Clin Rheumatol. 2001;20:353-8.
Low incidence of reactive arthritis in children following a salmonella outbreak. Rudwaleit M, Richter S, Braun J, Sieper J. Ann Rheum Dis. 2001;60:1055-7.
Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. Kuon W, Holzhutter HG, Appel H, Grolms M, Kollnberger S, Traeder A, Henklein P, Weiss E, Thiel A, Lauster R, Bowness P, Radbruch A, Kloetzel PM, Sieper J. J Immunol. 2001;167:4738-46.
Pathogenesis of reactive arthritis. Sieper J. Curr Rheumatol Rep. 2001;3:412-8.
New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. Curr Opin Rheumatol. 2001;13:245-9.
Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J. Ann Rheum Dis. 2001;60:337-43.
Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J. Ann Rheum Dis. 2001;60:36-42.
2000
Treatment of reactive arthritis: a practical guide. Rudwaleit M, Braun J, Sieper J. BioDrugs. 2000;13:21-8.
Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J. Arthritis Rheum. 2000;43:2834-42.
Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Braun J, Khan MA, Sieper J. Ann Rheum Dis. 2000;59:985-94.
Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. Moos V, Rudwaleit M, Herzog V, Hohlig K, Sieper J, Muller B. Arthritis Rheum. 2000;43:2417-22.
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences. Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siegert S, Radbruch A, Thiel A, Sieper J. Ann Rheum Dis. 2000;59 Suppl 1:i85-9.
On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. Braun J, Kingsley G, van der Heijde D, Sieper J. J Rheumatol. 2000;27:2185-92.
Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J. Osteoporos Int. 2000;11:400-7.
The possible role of myocardial biopsy in systemic sclerosis. Liangos O, Neure L, Kuhl U, Pauschinger M, Sieper J, Distler A, Schwimmbeck PL, Braun J. Rheumatology (Oxford). 2000;39:674-9.
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Arthritis Rheum. 2000;43:1346-52.
Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !? Braun J, Sieper J. Ann Rheum Dis. 2000;59:404-7.
Report on the Fourth International Workshop on Reactive Arthritis. Sieper J, Braun J, Kingsley GH. Arthritis Rheum. 2000;43:720-34.
Imaging of sacroiliitis. Braun J, Sieper J, Bollow M. Clin Rheumatol. 2000;19:51-7.
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J, Sieper J. Ann Rheum Dis. 2000;59:311-4.
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J. Ann Rheum Dis. 2000;59:135-40.
Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. Mertz AK, Wu P, Sturniolo T, Stoll D, Rudwaleit M, Lauster R, Braun J, Sieper J. J Immunol. 2000;164:1529-37.
|
.png)
